The SELECT trial of semaglutide in patients with overweight or obesity without diabetes: establishing a new pathway to secondary prevention of cardiovascular disease

被引：2
|
作者：
Lincoff, A. Michael [1 ]
Ryan, Donna H. [2 ]
机构：
[1] Case Western Reserve Univ, Cleveland Clin, Lerner Coll Med, Dept Cardiovasc Med, Cleveland, OH USA
[2] Pennington Biomed Res Ctr, Baton Rouge, LA USA
来源：
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY | 2024年 / 10卷 / 02期
关键词：
D O I：
10.1093/ehjcvp/pvad097
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：93 / 94
页数：2
相关论文
共 50 条
  • [1] Semaglutide for the secondary prevention of cardiovascular disease in people with overweight or obesity, but without diabetes: a cost-effectiveness analysis
    Zomer, E.
    Zhou, J.
    Nelson, A. J.
    Nicholls, S. J.
    Stub, D.
    Zoungas, S.
    EUROPEAN HEART JOURNAL, 2024, 45
  • [2] Semaglutide for the secondary prevention of cardiovascular disease in people with overweight or obesity, but without diabetes: a cost-effectiveness analysis
    Zomer, E.
    Zhou, J.
    Nelson, A. J.
    Nicholls, S. J.
    Stub, D.
    Zoungas, S.
    EUROPEAN HEART JOURNAL, 2024, 45
  • [3] SELECT semaglutide to improve outcomes in patients with obesity and cardiovascular disease, also without diabetes
    Gajos, Grzegorz
    CARDIOLOGY JOURNAL, 2024, 31 (05) : 782 - 783
  • [4] SEMAGLUTIDE, INFLAMMATORY MARKERS AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH OVERWEIGHT OR OBESITY IN THE SELECT TRIAL
    Plutzky, Jorge
    Bogdanski, Pawel
    Dagdelen, Selcuk
    Deanfield, John
    Emerson, Scott
    Hovingh, G.
    Kahn, Steven
    Larsen, Signe
    Latkovskis, Gustavs
    Lehrke, Michael
    Hardt-Lindberg, Soren
    Lingvay, Ildiko
    Nicholls, Stephen
    Oral, Tugce
    Terns, Paula Perez
    Rasmussen, Soren
    Ridker, Paul
    Ryan, Donna
    Lincoff, A. Michael
    ATHEROSCLEROSIS, 2024, 395
  • [5] Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial
    Kahn, Steven E.
    Deanfield, John E.
    Jeppesen, Ole Kleist
    Emerson, Scott S.
    Boesgaard, Trine Wellov
    Colhoun, Helen M.
    Kushner, Robert F.
    Lingvay, Ildiko
    Burguera, Bartolome
    Gajos, Grzegorz
    Horn, Deborah Bade
    Hramiak, Irene M.
    Jastreboff, Ania M.
    Kokkinos, Alexander
    Maeng, Michael
    Matos, Ana Laura S. A.
    Tinahones, Francisco J.
    Lincoff, A. Michael
    Ryan, Donna H.
    DIABETES CARE, 2024, 47 (08)
  • [6] Effect of semaglutide on kidney outcomes in people with overweight or obesity and established cardiovascular disease in the SELECT trial
    Colhoun, Helen M.
    Lingvay, Ildiko
    Brown, Paul M.
    Deanfield, John
    Brown-Frandsen, Kirstine
    Kahn, Steven E.
    Plutzky, Jorge
    Node, Koichi
    Parkhomenko, Alexander
    Ryden, Lars
    Wilding, John P. H.
    Mann, Johannes F. E.
    Tuttle, Katherine R.
    Idorn, Thomas
    Rathor, Naveen
    Lincoff, A. Michael
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39
  • [7] Effect of semaglutide on kidney outcomes in people with overweight or obesity and established cardiovascular disease in the SELECT trial
    Colhoun, Helen M.
    Lingvay, Ildiko
    Brown, Paul M.
    Deanfield, John
    Brown-Frandsen, Kirstine
    Kahn, Steven E.
    Plutzky, Jorge
    Node, Koichi
    Parkhomenko, Alexander
    Ryden, Lars
    Wilding, John P. H.
    Mann, Johannes F. E.
    Tuttle, Katherine R.
    Idorn, Thomas
    Rathor, Naveen
    Lincoff, A. Michael
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 : I1128 - I1130
  • [8] THE COST-EFFECTIVENESS OF SEMAGLUTIDE 2.4MG IN PATIENTS WITH OVERWEIGHT/OBESITY AND CARDIOVASCULAR DISEASE FROM THE SELECT TRIAL
    McEwan, P.
    Bog, M.
    Faurby, M.
    Foos, V
    Lingvay, I
    Lubker, C.
    Miller, R.
    Toliver, J.
    Yeates, F.
    Lincoff, A. M.
    VALUE IN HEALTH, 2024, 27 (06) : S148 - S148
  • [9] Semaglutide Improves Cardiovascular Outcomes in Patients with a History of Coronary Artery Bypass Surgery and Overweight or Obesity: The SELECT Trial
    Verma, Subodh
    Emerson, Scott
    Plutzky, Jorge
    Kahn, Steven
    Stensen, Signe
    Weeke, Peter
    Rasmussen, Soren
    Poirier, Paul
    Lingvay, Ildiko
    Lincoff, Abraham
    CIRCULATION, 2024, 150 (25) : E742 - E743
  • [10] The Composite Number Needed to Treat for Semaglutide in Populations with Overweight or Obesity and Established Cardiovascular Disease Without Diabetes
    Christopher Lübker
    Jigish Bhavsar
    Ruben Duque do Vale
    Scott S. Emerson
    Emil Nørtoft
    Jorge Plutzky
    Geraint Roberts
    Jens Magelund Tarp
    A. Michael Lincoff
    Advances in Therapy, 2025, 42 (5) : 2513 - 2525
12345